Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Eledon Pharmaceuticals, Inc.
Report date April 30, 2019 · Filed May 02, 2019
Jointly reported with LIFESCI INDEX PARTNERS LLC
Section 16 reporting ended · disclosed 2019-05-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.01 per shareSEC Table I · non-derivative | IndirectSee Footnote | 1,065,867 |
Reported balance
After 2019-04-30 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2019-04-30 · Sale · Disposed 200 · Balance 1,065,867 F1: The Common Stock is held in the accounts of private investment funds managed by LifeSci Index Partners LLC and may be deemed to be beneficially owned by Paul Yook, a principal of LifeSci Index Partners LLC. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein, and affirmatively disclaims being a "group" for purposes of Section 16 of the Securities Exchange Act of 1934, as amended. |
Filing footnotes · ownership attribution and instrument terms
F1: The Common Stock is held in the accounts of private investment funds managed by LifeSci Index Partners LLC and may be deemed to be beneficially owned by Paul Yook, a principal of LifeSci Index Partners LLC. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein, and affirmatively disclaims being a "group" for purposes of Section 16 of the Securities Exchange Act of 1934, as amended.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 30, 2019 Filed May 2, 2019 16:47 UTC | Eledon Pharmaceuticals, Inc. NVUS · Entity 6160 | SaleCommon Stock, par value $0.01 per share | 200 | $2.70 | $540.00 |
DisclosureSEC source: 0000919574-19-003096 · ownership.xml · nonDerivative · entry 1 LIFESCI INDEX PARTNERS LLC · CIK 0001734312 · 10% owner YOOK PAUL · CIK 0001735029 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,065,867 F1 · ownership.nature: The Common Stock is held in the accounts of private investment funds managed by LifeSci Index Partners LLC and may be deemed to be beneficially owned by Paul Yook, a principal of LifeSci Index Partners LLC. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein, and affirmatively disclaims being a "group" for purposes of Section 16 of the Securities Exchange Act of 1934, as amended. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.